Blood test guided monitoring for advanced lung cancer treatment
Part of Cancer, Lungs & breathing clinical trials.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed, confirmed non-small cell lung cancer (NSCLC)
- Your cancer is advanced or locally advanced and cannot be cured with standard curative treatment
- You are over 18 years old
- You can take care of yourself most of the time (ECOG performance status 0–1)
- Your scans show measurable disease (you have measurable spots the study can track)
- You are able to start immunotherapy as the first treatment using just one immunotherapy medicine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This trial is for people with advanced non-small cell lung cancer (NSCLC) who have not yet started treatment. It studies a simple blood test that checks for genetic changes in the cancer, to help doctors choose the most effective first treatment.
This study uses a simple blood test to look at bits of tumor DNA (called circulating tumor DNA) to see how well your targeted therapy (TKI) is working. It helps doctors predict and monitor whether the treatment is effective for your advanced lung cancer.
This trial uses a simple blood test during chemotherapy before surgery to see how well the treatment is working. It is for people with operable lung cancer that has an EGFR mutation, and may help guide their treatment.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.